Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia.

Manns B, Hyndman E, Burgess E, Parsons H, Schaefer J, Snyder F, Scott-Douglas N.

Kidney Int. 2001 Mar;59(3):1103-9.

2.

Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease.

Manns BJ, Burgess ED, Hyndman ME, Parsons HG, Schaefer JP, Scott-Douglas NW.

Am J Kidney Dis. 1999 Oct;34(4):669-77.

PMID:
10516348
3.

ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins.

Sydow K, Schwedhelm E, Arakawa N, Bode-Böger SM, Tsikas D, Hornig B, Frölich JC, Böger RH.

Cardiovasc Res. 2003 Jan;57(1):244-52.

PMID:
12504835
4.

Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.

Gonin JM, Nguyen H, Gonin R, Sarna A, Michels A, Masri-Imad F, Bommareddy G, Chassaing C, Wainer I, Loya A, Cary D, Barker LF, Assefi A, Greenspan R, Mahoney D, Wilcox CS.

J Nephrol. 2003 Jul-Aug;16(4):522-34.

PMID:
14696754
5.

Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12 and folate.

Henning BF, Zidek W, Riezler R, Graefe U, Tepel M.

Res Exp Med (Berl). 2001 Mar;200(3):155-68.

PMID:
11426667
6.

Oral folate reduces plasma homocyst(e)ine levels in hemodialysis patients with cardiovascular disease.

Stanford JL, Molina H, Phillips J, Kohlman-Trigoboff D, Moore J, Smith BM.

Cardiovasc Surg. 2000 Dec;8(7):567-71.

PMID:
11068219
7.

[Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options].

Sydow K, Böger RH.

Z Kardiol. 2001 Jan;90(1):1-11. Review. German.

PMID:
11220081
9.

Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: a randomized controlled trial.

Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A.

J Clin Endocrinol Metab. 2001 Apr;86(4):1518-24.

PMID:
11297577
10.

Hyperhomocyst(e)inemia--determining factors and treatment.

Genest J Jr.

Can J Cardiol. 1999 Apr;15 Suppl B:35B-38B.

PMID:
10350684
11.

Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients.

Azadibakhsh N, Hosseini RS, Atabak S, Nateghiyan N, Golestan B, Rad AH.

Saudi J Kidney Dis Transpl. 2009 Sep;20(5):779-88.

12.

Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys.

Lentz SR, Malinow MR, Piegors DJ, Bhopatkar-Teredesai M, Faraci FM, Heistad DD.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2930-4.

PMID:
9409278
13.

Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine.

Ducloux D, Fournier V, Rebibou JM, Bresson-Vautrin C, Gibey R, Chalopin JM.

Clin Nephrol. 1998 Apr;49(4):232-5.

PMID:
9582553
14.

Rationale and design for the CARDIOVIT Study (Cardiovit, Atherosclerotic vascular disease and hypeRhomocysteinemia: an epiDemiological study in Indians, additionally evaluating the effect of Oral VITamin supplementation).

Shenoy KT, Lena KB, Sali N, Syam S, Shenoy ST, Rajadhyaksha VD, Pai GP, Shaikh AA; Cardiovit Study Team.

Curr Med Res Opin. 2006 Apr;22(4):641-8.

PMID:
16684424
15.

Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients.

Bostom AG, Shemin D, Bagley P, Massy ZA, Zanabli A, Christopher K, Spiegel P, Jacques PF, Dworkin L, Selhub J.

Circulation. 2000 Jun 20;101(24):2829-32. Erratum in: Circulation 2000 Aug 1;102(5):598.

PMID:
10859289
16.

Potential clinical and economic effects of homocyst(e)ine lowering.

Nallamothu BK, Fendrick AM, Rubenfire M, Saint S, Bandekar RR, Omenn GS.

Arch Intern Med. 2000 Dec 11-25;160(22):3406-12.

PMID:
11112233
17.

Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease.

Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, Gluckman RA, Block PC, Upson BM.

N Engl J Med. 1998 Apr 9;338(15):1009-15.

18.

Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease.

Ziegler S, Mittermayer F, Plank C, Minar E, Wolzt M, Schernthaner GH.

J Clin Endocrinol Metab. 2005 Apr;90(4):2175-8. Epub 2005 Jan 5.

PMID:
15634723
19.

Homocyst(e)ine and atherosclerosis in patients on chronic hemodialysis.

Lee YK, Kwon YJ, Yoon JW, Oh KS, Cha DR, Cho WY, Huh K, Pyo HJ, Kim HK.

J Korean Med Sci. 1999 Apr;14(2):193-8.

20.

Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients.

Nakhoul F, Abassi Z, Plawner M, Khankin E, Ramadan R, Lanir N, Brenner B, Green J.

Isr Med Assoc J. 2004 Apr;6(4):213-7.

Supplemental Content

Support Center